Initial Statement of Beneficial Ownership (3)
29 October 2020 - 2:21AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Creamer Victoria L |
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/20/2020
|
3. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [CRL]
|
(Last)
(First)
(Middle)
251 BALLARDVALE STREET |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) EVP & Chief People Officer / |
(Street)
WILMINGTON, MA 01887
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 5879 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options (Right to Buy) | 2/1/2020 | 2/1/2024 | Common Stock | 4290 (2) | $124.13 | D | |
Stock Options (Right to Buy) | 2/22/2020 | 2/22/2024 | Common Stock | 6761 (3) | $144.67 | D | |
Stock Options (Right to Buy) | 5/29/2021 | 5/29/2030 | Common Stock | 5571 (4) | $179.66 | D | |
Explanation of Responses: |
(1) | Consists of: (a) 754 shares of common stock; (b) 5,125 unvested restricted stock units which vest as follows: 755 on Feb 1, 2021, 397 on Feb 22, 2021, 417 on May 9, 2021, 755 on Feb 1, 2022, 396 on Feb 22, 2022, 418 on May 29, 2022, 755 on Feb 1, 2023, 397 on Feb 22, 2023, 417 on May 29, 2023 and 418 on May 29, 2024. |
(2) | 1,072 Stock Options have vested as of the reporting date. The remaining 3,218 stock options will vest as follows: 1,073 on Feb 1, 2021, 1,072 on Feb 1, 2022 and 1,073 on Feb 1, 2023. |
(3) | 1,690 Stock Options have vested as of the reporting date. The remaining 5,071 stock options will vest as follows: 1,690 on Feb 22, 2021, 1,690 on Feb 22, 2022 and 1,691 on Feb 22, 2023. |
(4) | Stock Options will vest as follows: 1,392 on May 29, 2021, 1,393 on May 29, 2022, 1,393 on May 29, 2023 and 1,393 on May 29, 2024. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Creamer Victoria L 251 BALLARDVALE STREET WILMINGTON, MA 01887 |
|
| EVP & Chief People Officer |
|
Signatures
|
/s/ Victoria L. Creamer | | 10/28/2020 |
**Signature of Reporting Person | Date |
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2024 to May 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2023 to May 2024